Showing posts with label primaquine. Show all posts
Showing posts with label primaquine. Show all posts

Sunday, 1 May 2011

MALARIA: Plasmodium knowlesi in children in Malaysia

Plasmodium knowlesi can cause severe malaria in adults; however, descriptions of clinical disease in children are lacking. We reviewed case records of children (age <15 years) with a malaria diagnosis at Kudat District Hospital, serving a largely deforested area of Sabah, Malaysia, during January–November 2009. Sixteen children with PCR-confirmed P. knowlesi monoinfection were compared with 14 children with P. falciparum monoinfection diagnosed by microscopy or PCR. Four children with knowlesi malaria had a hemoglobin level at admission of <10.0 g/dL (minimum lowest level 6.4 g/dL). Minimum level platelet counts were lower in knowlesi than in falciparum malaria (median 76,500/μL vs. 156,000/mL; p = 0.01). Most (81%) children with P. knowlesi malaria received chloroquine and primaquine; median parasite clearance time was 2 days (range 1–5 days). P. knowlesi is the most common cause of childhood malaria in Kudat. Although infection is generally uncomplicated, anemia is common and thrombocytopenia universal. Transmission dynamics in this region require additional investigation.
http://www.cdc.gov/eid/content/17/5/814.htm

Tuesday, 28 December 2010

MALARIA: The reality of using primaquine

Kathy Burgoine et al. Malaria Journal 2010, 9:376  Published: 27 December 2010

Background
Primaquine is currently the only medication used for radical cure of Plasmodium vivax infection. Unfortunately, its use is not without risk. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency have an increased susceptibility to haemolysis when given primaquine. This potentially fatal clinical syndrome can be avoided if patients are tested for G6PD deficiency and adequately informed before being treated.

Case presentation
A 35-year old male presented to our clinic on the Thai-Burmese border with a history and clinical examination consistent with intravascular haemolysis. The patient had been prescribed primaquine and chloroquine four days earlier for a P. vivax infection. The medication instructions had not been given in a language understood by the patient and he had not been tested for G6PD deficiency. The patient was not only G6PD deficient but misunderstood the instructions and took all his primaquine tablets together. With appropriate treatment the patient recovered and was discharged home a week later.

Conclusions
Whilst primaquine remains the drug of choice to eradicate hypnozoites and control P. vivax transmission, the risks associated with its use must be minimized during its deployment. In areas where P. vivax exists, patients should be tested for G6PD deficiency and adequately informed before administration of primaquine.
http://www.malariajournal.com/content/9/1/376

Friday, 29 October 2010

MALARIA: Experts say efforts to beat malaria may backfire

29 October 2010
Neil Bowdler

The mosquito carries the malaria parasites
The mosquito is responsible for carrying the malaria parasite from human to human Efforts to eradicate malaria in some countries may be counter-productive, an international team of researchers suggest.

In the Lancet, they suggest some countries, particularly in sub-Saharan Africa, may be better pursing a policy of controlling the disease.
They also criticise the World Health Organization (WHO) for not providing adequate direction.
But a WHO spokesman said beating malaria must remain the ultimate goal.
'Noble' goal
The Lancet looks at the feasibility of eradicating malaria from the map, in the same way smallpox was conquered.
As the report points out, the Bill and Melinda Gates Foundation set the world such a target in 2007, an aim which was then endorsed by the WHO's Director-General Margaret Chan.
The Lancet concludes such a goal, while noble, "could lead to dangerous swings in funding and political commitment, in malaria and elsewhere".

Malaria facts
Largely preventable and curable
In 2008 caused a million deaths - mostly African children
About 2,000 return to the UK with malaria every year
Only 12% of these become seriously ill
Symptoms can take up to a year to appear

And the WHO is accused of failing "to rise to their responsibilities to give the malaria community essential direction".
The series of articles instead urges a pragmatic approach in which efforts and resources are concentrated on shrinking the global area where malaria still prevails.
It suggests some countries, particularly in sub-Saharan Africa, may be better pursuing a policy of controlling the disease rather than one of eradication.
The report's authors include Professor Richard Feacham of University of California's Global Health Group and researchers from the Clinton Health Access Initiative.
Saving lives
In an editorial accompanying the series, the Lancet's editor-in-chief Dr Richard Horton and executive editor Dr Pamela Das, argue control may save more lives.
"If existing control efforts were indeed scaled up, by 2015, 1.14 million children's lives could be saved in sub-Saharan Africa alone. This finding is important. The quest for elimination must not distract existing good malaria control work," they write.
They also conclude that "malaria will only be truly eradicable when an effective vaccine is fully available".
Responding to the report in a statement, Robert Newman, director of the WHO's Global Malaria Programme, said the ultimate goal had to be eradication
"WHO has always supported - and will always continue to support - endemic countries in their efforts to control and eliminate malaria," he writes.
"It is entirely feasible to eliminate malaria from countries and regions where the intensity of transmission is low to moderate, and where health systems are strong.
"Eliminating malaria from countries where the intensity of transmission is high and stable, such as in tropical Africa, will require more potent tools and stronger health systems than are available today."

A global malaria map

Shrinking map

Malaria is caused by five species of a parasite that can be carried from human to human by mosquitoes.
Over the last 150 years, the portion of the world where malaria is still endemic has shrunk, but the disease is still endemic in 99 countries.
However 32 of these countries, most of them on the edges of the endemic zone, are attempting to eradicate the disease, while the rest are trying to reduce infections and deaths though control measures.
But switching from a policy of controlling the disease to one of eradication brings with it problems and risks, according to the report.
The authors point out that malaria and mosquitoes do not respect national borders and that both parasite and insect may develop resistance to existing drugs.
They also warn switching funds from control to eradication may negatively impact upon measures which have been shown to reduce infection and mortality.
The picture is further complicated by the fact that countries are dealing with two main malaria parasite species - Plasmodium falciparum and Plasmodium vivax.
While there is more research available on the former and more drugs available to combat it, most of the countries trying to eliminate malaria currently are largely threatened by the latter species P vivax.
A combination of drugs from the artemisinin family are generally used to tackle P falciparum while primaquine is the only registered drug available to combat P vivax.
The Gates Foundation was unavailable for comment.

http://www.bbc.co.uk/news/health-11643868

Friday, 15 October 2010

MALARIA: Australia Defence Force Experience

We report here a retrospective analysis of all malaria cases in military personnel reported to the Australian Defence Force (ADF) Central Malaria Register from 1998 to 2007.
A total of 637 cases of malaria were notified affecting 487 individuals. Of these 85.9% (547) were infected with Plasmodium vivax malaria and 10.2% (65) with P. falciparum malaria. The majority of cases were from Timor Leste (78.5%, 501/637). Malaria attack rates of 0.9% (369/40 571), 1.1% (52/4776) and 0.4% (20/5345) were seen in Timor Leste, Bougainville and the Solomon Islands, respectively. The median period following departure from a malarious country to presentation of P. falciparum was 17 d (range 1–47 d) and for a primary presentation of P. vivax malaria was 86 d (range 1–505 d). Increasing the dose of primaquine from 22.5 mg daily to 30 mg daily for 14 d for radical cure of P. vivax malaria reduced the failure rate from 46.6% (35/75) to 9.4% (17/181) in subjects returning from Timor Leste.

Malaria remains a serious problem for ADF soldiers deploying to malarious areas, particularly the incidence of relapsing vivax malaria and the tolerance of these vivax strains to primaquine.

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B985R-4YWJHV9-1&_user=10&_coverDate=06%2F30%2F2010&_rdoc=1&_fmt=high&_orig=search&_origin=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=d368db0726ce19fa3fe99019b4513580&searchtype=a

Sunday, 5 September 2010

MALARIA: Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia

02 September 2010
Plasmodium vivax is the second most important cause of morbidity in Ethiopia. There is, however, little information on P. vivax resistance to chloroquine and chloroquine plus primaquine treatment although these drugs have been used as the first line treatment for over 50 years. We assessed the efficacy of standard chloroquine and chloroquine plus primaquine treatment for P. vivax infections in a randomized open-label comparative study in Debre Zeit and Nazareth in East Shoa, Ethiopia.A total of 290 patients with microscopically confirmed P. vivax malaria who presented to the outpatient settings of the two laboratory centers were enrolled: 145 patients were randomized to receive CQ and 145 to receive CQ+ PQ treatment. Participants were followed-up for 28–157 days according to the WHO procedures. There were 12 (6.5%) lost to follow-up patients and 9 (3.1%) withdrawals. In all, 96% (277/290) of patients were analysed at day 28. Baseline characteristics were similar in all treatment groups. In all, 98.6% (275/277) of patients had cleared their parasitemia on day 3 with no difference in mean parasite clearance time between regimens (48.34±17.68, 50.67±15.70 h for the CQ and CQ+ PQ group, respectively, P = 0.25). The cumulative incidence of therapeutic failure at day 28 by a life-table analysis method was 5.76% (95% CI: 2.2–14.61) and 0.75% (95% CI: 0.11–5.2%) in the CQ and CQ+ PQ group, respectively (P = 0.19). The relapse rate was 8% (9/108) for the CQ group and 3% (4/132) for the comparison group (P = 0.07). The cumulative risk of relapse at day 157 by a life-table method was 61.8% (95% CI: 20.1–98.4%) in the CQ group, compared with 26.3% (95% CI: 7.5–29.4%) in the CQ+ PQ group (P = 0.0038).


The study confirms the emergence of CQ and PQ resistance/treatment failure in P. vivax malaria in Ethiopia. Although treatment failures were detected, they were similar between the treatment groups. We recommend regular monitoring and periodic evaluation of the efficacy of these antimalarial drugs in systematically selected sentinel sites to detect further development of resistance and to make timely national antimalarial drug policy changes.
http://www.malarianexus.com/articles/read/47/therapeutic-efficacy-of-chloroquine-and-chloroquine-plus-primaquine-for-the-treatment-of-plasmodium-vivax-in-ethiopia/

Thursday, 12 August 2010

MALARIA: Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia

30 July 2010
Plasmodium vivax is the second most important cause of morbidity in Ethiopia. There is, however, little information on P. vivax resistance to chloroquine and chloroquine plus primaquine treatment although these drugs have been used as the first line treatment for over 50 years. We assessed the efficacy of standard chloroquine and chloroquine plus primaquine treatment for P. vivax infections in a randomized open-label comparative study in Debre Zeit and Nazareth in East Shoa, Ethiopia.A total of 290 patients with microscopically confirmed P. vivax malaria who presented to the outpatient settings of the two laboratory centers were enrolled: 145 patients were randomized to receive CQ and 145 to receive CQ+ PQ treatment. Participants were followed-up for 28–157 days according to the WHO procedures. There were 12 (6.5%) lost to follow-up patients and 9 (3.1%) withdrawals. In all, 96% (277/290) of patients were analysed at day 28. Baseline characteristics were similar in all treatment groups. In all, 98.6% (275/277) of patients had cleared their parasitemia on day 3 with no difference in mean parasite clearance time between regimens (48.34±17.68, 50.67±15.70 h for the CQ and CQ+ PQ group, respectively, P = 0.25). The cumulative incidence of therapeutic failure at day 28 by a life-table analysis method was 5.76% (95% CI: 2.2–14.61) and 0.75% (95% CI: 0.11–5.2%) in the CQ and CQ+ PQ group, respectively (P = 0.19). The relapse rate was 8% (9/108) for the CQ group and 3% (4/132) for the comparison group (P = 0.07). The cumulative risk of relapse at day 157 by a life-table method was 61.8% (95% CI: 20.1–98.4%) in the CQ group, compared with 26.3% (95% CI: 7.5–29.4%) in the CQ+ PQ group (P = 0.0038). The study confirms the emergence of CQ and PQ resistance/treatment failure in P. vivax malaria in Ethiopia. Although treatment failures were detected, they were similar between the treatment groups. We recommend regular monitoring and periodic evaluation of the efficacy of these antimalarial drugs in systematically selected sentinel sites to detect further development of resistance and to make timely national antimalarial drug policy changes.

http://www.malarianexus.com/articles/read/47/therapeutic-efficacy-of-chloroquine-and-chloroquine-plus-primaquine-for-the-treatment-of-plasmodium-vivax-in-ethiopia